{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T08:53:45Z","timestamp":1760864025655},"reference-count":25,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Responders to cardiac resynchronisation therapy whose device has a defibrillator component and who do not receive a therapy in the lifetime of the first generator have a very low incidence of appropriate therapy after box change. We investigated the cost implications of using a risk stratification tool at the time of generator change resulting in these patients being reimplanted with a resynchronisation pacemaker.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A decision tree was created using previously published data which had demonstrated an annualised appropriate defibrillator therapy risk of 2.33%. Costs were calculated at National Health Service (NHS) national tariff rates (2016\u20132017). EQ-5D utility values were applied to device reimplantations, admissions and mortality data, which were then used to estimate quality-adjusted life-years (QALYs) over 5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 5 years, the incremental cost of replacing a resynchronisation defibrillator device with a second resynchronisation defibrillator versus resynchronisation pacemaker was \u00a35045 per patient. Incremental QALY gained was 0.0165 (defibrillator vs pacemaker), resulting in an incremental cost-effectiveness ratio (ICER) of \u00a3305\u2009712 per QALYs gained. Probabilistic sensitivity analysis resulted in an ICER of \u00a3313\u2009612 (defibrillator vs pacemaker). For reimplantation of all patients with a defibrillator rather than a pacemaker to yield an ICER of less than \u00a330\u2009000 per QALY gained (current NHS cut-off for approval of treatment), the annual arrhythmic event rate would need to be 9.3%. The budget impact of selective replacement was a saving of \u00a32 133 985 per year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Implanting low-risk patients with a resynchronisation defibrillator with the same device at the time of generator change is not cost-effective by current NHS criteria. Further research is required to understand the impact of these findings on individual patients at the time of generator change.<\/jats:p><\/jats:sec>","DOI":"10.1136\/heartjnl-2017-311749","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T01:20:22Z","timestamp":1506993622000},"page":"416-422","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of a risk-stratified approach to cardiac resynchronisation therapy defibrillators (high versus low) at the time of generator change"],"prefix":"10.1136","volume":"104","author":[{"given":"Simon","family":"Claridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic A","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Fearn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M","family":"Behar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Sieniewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaswinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"2020050721432358000_104.5.416.1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eup274"},{"key":"2020050721432358000_104.5.416.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050496"},{"key":"2020050721432358000_104.5.416.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht150"},{"key":"2020050721432358000_104.5.416.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032423"},{"key":"2020050721432358000_104.5.416.5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001289"},{"key":"2020050721432358000_104.5.416.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.025"},{"key":"2020050721432358000_104.5.416.7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/jce.12496","article-title":"Positive response to cardiac resynchronization therapy reduces arrhythmic events after elective generator change in patients with primary prevention CRT-D","volume":"25","author":"Sebag","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2020050721432358000_104.5.416.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv373"},{"key":"2020050721432358000_104.5.416.9","doi-asserted-by":"crossref","unstructured":"England NHS. Five year forward view. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2014\/10\/5yfv-web.pdf (accessed Jan 5 2017).","DOI":"10.1007\/s40274-014-1663-8"},{"key":"2020050721432358000_104.5.416.10","unstructured":"NICOR and British heart Rhythm Society. National Audit of Cardiac Rhythm Management Devices 2014-15. https:\/\/www.ucl.ac.uk\/nicor\/audits\/cardiacrhythm\/documents\/annual-reports\/cardiac_rhythm_management_devices_public_report_2014_15 (accessed Jan 19 2017)."},{"key":"2020050721432358000_104.5.416.11","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307634"},{"key":"2020050721432358000_104.5.416.12","unstructured":"Kind P . The EuroQol instrument: An index of health related quality of life.. In: Spiker B , ed. Quality of life and PharmacoEconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers, 1996."},{"key":"2020050721432358000_104.5.416.13","first-page":"83","article-title":"Modelling the cost-effectiveness of cardiac interventions: the case of sirolimus-eluting stents","volume":"12","author":"Hawkins","year":"2005","journal-title":"Br J Cardiol"},{"key":"2020050721432358000_104.5.416.14","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013;93:1. http:\/\/www.nice.org.uk\/media\/D45\/1E\/GuideToMethodsTechnologyAppraisal2013.pdf."},{"key":"2020050721432358000_104.5.416.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2016.04.009"},{"key":"2020050721432358000_104.5.416.16","unstructured":"National Institute for Health and Care Excellence. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120). 2014."},{"key":"2020050721432358000_104.5.416.17","first-page":"72","article-title":"Assessing the health-related quality of life in patients hospitalised for Acute heart failure. Br","volume":"20","author":"Swinburn","year":"2013","journal-title":"J Cardiol"},{"key":"2020050721432358000_104.5.416.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.12.003"},{"key":"2020050721432358000_104.5.416.19","unstructured":"Monitor and NHS England. National Tariff Payment System 2016-17. https:\/\/www.gov.uk\/government\/publications\/nhs-national-tariff-payment-system-2016\/17 (accessed Jan 19 2017)."},{"key":"2020050721432358000_104.5.416.20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1001\/jamainternmed.2014.3435","article-title":"Decision making at the time of ICD generator change: patients' perspectives","volume":"174","author":"Lewis","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2020050721432358000_104.5.416.21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jamainternmed.2013.3171","article-title":"Patient perceptions, physician communication, and the implantable cardioverter-defibrillator","volume":"173","author":"Hauptman","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2020050721432358000_104.5.416.22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"2020050721432358000_104.5.416.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.12.020"},{"key":"2020050721432358000_104.5.416.24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/jce.13226","article-title":"Substrate-dependent risk stratification for implantable cardioverter defibrillator therapies using cardiac magnetic resonance imaging: The importance of T1 mapping in nonischemic patients","volume":"28","author":"Claridge","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2020050721432358000_104.5.416.25","unstructured":"National Institute for Health and Care Excellence. ENDURALIFE powered CRT-D devices for treating heart failure. 2017;26 https:\/\/www.nice.org.uk\/guidance\/mtg33\/resources\/enduralife-powered-crt-d-devices-for-treating-heart-failure-64371993632197"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-311749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T21:27:49Z","timestamp":1659562069000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-311749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,2,12]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/heartjnl-2017-311749"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-311749","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]}}}